Featured Publications

Public Companies: Alert - September 2, 2010

On August 25, 2010, the SEC adopted new rules that require all U.S. public companies (and certain non-U.S. companies that comply with the U.S. proxy rules) to include in their proxy materials shareholder director nominees and shareholder proposals that seek to regulate the nomination and election of directors.

More

Chambers USA Lists Holland & Knight Among Nation’s Top Law Firms, Earning Top Spots in Multiple Practice Areas and Markets

More than 100 Holland & Knight attorneys named America’s Leading Lawyers in 2009 Chambers USA Guide.

More

Search Our Library

Search

  • Printer friendly
  • Email this page to a friend
  • Generate a PDF version of this page

In The Headlines

Health Reform Seen as Providing Benefits, Challenges for Life Sciences Companies
 

BNA Medical Devices Law & Industry Report

June 2, 2010
 
Michael M. Gaba- Washington
Jennifer A. Short- Washington
Michael J. Werner- Washington

Healthcare & Life Sciences Partners Michael Gaba, Michael Werner and Jennifer Short were featured in a BNA Medical Devices Law & Industry Report article summarizing Holland & Knight's May 26 webinar titled, "Health Care Reform: The Impact on Life Sciences Companies."

The online seminar explained how the new health reform laws will affect biopharmaceutical and medical device companies by assessing fees and taxes, providing tax credits for therapeutic discoveries, and requiring comparative clinical effectiveness research (CCER) that will be used to make spending decisions. "The media has emphasized the insurance changes, but there's a lot else in the new laws that affects life sciences companies," said Mr. Gaba. "And the fun is just beginning, especially because the laws give the secretary of health and human services substantial discretion in the implementation."

For up-to-date content and resources regarding the new Health Reform Bill, please visit Holland & Knight's Healthcare Reform Center.

Related Practices